Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Piperocaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 0.98 |
| ▸ | SCN2A known ✓ | Q99250 | 2/20 | 0.98 |
| ▸ | SCN3A known ✓ | Q9NY46 | 2/20 | 0.98 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.52 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 5/20 | 0.52 |
| ▸ | BCHE known ✓ | P06276 | 2/20 | 0.47 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.46 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperocaine SCHEMBL503032 | 1.00 | SCN1A (0.98) | SCN1ASCN2ASCN3ACHRNB2CHRNA5 | |
| Piperocaine SCHEMBL25713 | 0.99 | SCN1A (1.00) | SCN1ASCN2ASCN3ACHRNB2CHRNA5 | |
| Piperocaine SCHEMBL25714 | 0.99 | SCN1A (1.00) | SCN1ASCN2ASCN3ACHRNB2CHRNA5 | |
| Piperocaine SCHEMBL9224615 | 0.96 | SCN1A (0.95) | SCN1ASCN2ASCN3ACHRNB2CHRNA5 | |
| Piperocaine SCHEMBL9224611 | 0.96 | SCN1A (0.95) | SCN1ASCN2ASCN3ACHRNB2CHRNA5 | |
| Piperocaine SCHEMBL7615890 | 0.94 | SCN1A (0.91) | SCN1ASCN2ASCN3ACHRNB2CHRNA5 | |
| Cyclomethycaine SCHEMBL634210 | 0.84 | SCN1A (0.98) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Cyclomethycaine SCHEMBL634211 | 0.84 | SCN1A (0.98) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Biphenyl SCHEMBL23174836 | 0.83 | SCN1A (0.72) | SCN1ASCN2ASCN3AHRH3KMT2A | |
| Cyclomethycaine SCHEMBL25346 | 0.83 | SCN1A (1.00) | SCN1ASCN2ASCN3AHRH3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 554 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019155389-A1 | AN AQUEOUS MUCOADHESIVE AND BIOADHESIVE COMPOSITION FOR THE TREATMENT | TARGET ONCOLOGY INC. (US) | 2019-08-15 | — | — | WO | claimed |
| EP-1656080-B1 | DEVICE FOR DELIVERING AN ORAL CARE AGENT | RANIR LLC (US) | 2016-06-01 | — | — | EP | claimed |
| US-8956160-B2 | Device and method for delivering an oral care agent | RANIR, LLC (US) | 2015-02-17 | — | — | US | claimed |
| EP-2489329-A1 | Device and method for delivering an oral care agent | Ranir/DCP Corporation (US) | 2012-08-22 | — | — | EP | claimed |
| EP-1656080-A4 | DEVICE AND METHOD FOR DELIVERING AN ORAL CARE AGENT | RANIR DCP CORP (US) | 2007-11-14 | — | — | EP | claimed |
| EP-1809200-A2 | DEVICE AND METHOD FOR DELIVERING AN ORAL CARE AGENT | Ranir LLC (US) | 2007-07-25 | — | — | EP | claimed |
| EP-0615749-B1 | Use of NMDA antagonists for the treatment of pain | UNIV VIRGINIA COMMONWEALTH (US) | 2006-12-13 | — | — | EP | claimed |
| WO-2006052593-A2 | DEVICE AND METHOD FOR DELIVERING AN ORAL CARE AGENT | RANIR LLC (US) | 2006-05-18 | — | — | WO | claimed |
| EP-1656080-A2 | DEVICE AND METHOD FOR DELIVERING AN ORAL CARE AGENT | Ranir/DCP Corporation (US) | 2006-05-17 | — | — | EP | claimed |
| US-20060099550-A1 | Device and method for delivering an oral care agent | RANIR/DCP CORPORATION (US) | 2006-05-11 | — | — | US | claimed |
| US-20030044446-A1 | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds | MUCOADHESIVE ERODIBLE DRUG DELIVERY DEVICE FOR CONTROLLED ADMN. OF PHARMACEUTICALS & OTHER ACTI | 2003-03-06 | — | — | US | claimed |
| WO-2003015748-A2 | MUCOADHESIVE ERODIBLE DRUG DELIVERY DEVICE FOR CONTROLLED ADMINISTRATION OF PHARMACEUTICALS AND OTHER ACTIVE COMPOUNDS | ACCESS PHARMACEUTICALS, INC. (US) | 2003-02-27 | — | — | WO | claimed |
| US-20030022894-A1 | Imidazotriazinone-containing compositions for nasal administration | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-01-30 | — | — | US | claimed |
| US-20020006435-A1 | Transdermal anesthetic and vasodilator composition and methods for topical administration | SAMUELS PAUL J (US) | 2002-01-17 | — | — | US | claimed |
| WO-2001054679-A2 | TRANSDERMAL COMPOSITION CONTAINING AN ANESTHETIC AND A VASODILATOR AGENT | CHILDREN'S HOSPITAL RESEARCH FOUNDATION (US) | 2001-08-02 | — | — | WO | claimed |
| US-6159498-A | WATER-SOLUBLE DELIVERY DEVICE FOR APPLICATION TO MUCOSAL SURFACES | VIROTEX CORPORATION (US) | 2000-12-12 | — | — | US | claimed |
| EP-0850054-A4 | FORMULATIONS OF HALOALKYLAMINES AND LOCAL ANAESTHETICS AND METHODS FOR THE TREATMENT OF REFLEX SYMPATHETIC DYSTROPHY (RSD) | NEW YORK MEDICAL COLLEGE (US) | 2000-09-13 | — | — | EP | claimed |
| US-5898035-A | Formulations of haloalkylamines and local anesthetic and methods for the treatment of reflex sympathetic dystrophy (RSD) | NEW YORK MEDICAL COLLEGE (US) | 1999-04-27 | — | — | US | claimed |
| EP-0850054-A1 | FORMULATIONS OF HALOALKYLAMINES AND LOCAL ANAESTHETICS AND METHODS FOR THE TREATMENT OF REFLEX SYMPATHETIC DYSTROPHY (RSD) | NEW YORK MEDICAL COLLEGE (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997007793-A1 | FORMULATIONS OF HALOALKYLAMINES AND LOCAL ANAESTHETICS AND METHODS FOR THE TREATMENT OF REFLEX SYMPATHETIC DYSTROPHY (RSD) | NEW YORK MEDICAL COLLEGE (US) | 1997-03-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022894-A1 | Imidazotriazinone-containing compositions for nasal administration | PDE2A, PDE3A, PDE3B | SCN1A 83/4885SCN2A 50/4885SCN3A 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.